surpass cvot tirzepatide C. Michael Gibson MD on X: "SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. # Overview of key tirzepatide clinical

Joint pain and fatigue limit movement, and some RA medications, particularly corticosteroids, can contribute to weight gain

Genetic predispositions in peptide signaling pathways (GIPR, MC4R, FTO variants) can support more informed conversations with providers about expected dose ranges and titration pace, though they do not predict exact individual response

The European Council adopted a consensus position on the proposed pharmaceutical regulation and directive in June 2025

Site-specific pegylated Exendin-4 modified with a high molecular weight trimeric PEG reduces steric hindrance and increases type 2 antidiabetic therapeutic effects

GLP-1s are not just another diabetes medication